LGND Biotechnology · Royalties · Biotech · Small cap · Thesis updated July 1, 2026

Bigger royalty book, bigger execution test

Ligand is a biotech royalty aggregator, which means it gets paid when partners sell drugs tied to its rights.
Q1 2026 royalties rose 56% year over year to $43.0 million, driven by Filspari, Ohtuvayre, Capvaxive, and Kyprolis.
The pending XOMA deal would add over 120 assets, including exposure to Roche's Vabysmo.
Filspari gained FDA approval for FSGS on April 13, 2026, giving Ligand a larger rare kidney disease opportunity.
The bear case is real: Viking is disputing Ligand's TR-Beta termination, Captisol is lumpy, and older royalties face generic risk.

01 Running thesis

Scale helps, but price matters

Ligand is trying to be a cleaner way to own biotech upside. It does not need to build huge sales teams for every drug. Instead, it owns royalty rights and gets paid when partner drugs sell.

The thesis moved up in 2026 because two big things happened. Ligand agreed to buy XOMA, another royalty aggregator, in a deal expected to close in Q3 2026. XOMA would add over 120 commercial, clinical, and preclinical assets. Soon after, Travere's Filspari won FDA approval for FSGS, a second rare kidney disease use.

The same period also added new risk. Ligand terminated its TR-Beta license agreement with Viking Therapeutics, including VK2809 and VK0214, and Viking is disputing that move. If Ligand loses the argument, it could lose leverage over a potentially valuable program or spend money fighting it.

Finn's view is mixed. Business performance is strong, especially royalty growth, but the stock still has to prove that XOMA was bought well, integrated well, and that new royalties can offset future generic pressure.

May 2026▲Ligand announced a definitive agreement to acquire XOMA, which would add over 120 assets, and Filspari won FDA approval for FSGS. The update was tempered by Viking disputing Ligand's TR-Beta termination and a 36% drop in Captisol revenue.

Feb 2026▲The 2025 Form 10-K confirmed 48% royalty growth for the year and positive Phase 3 data for Palvella's Qtorin rapamycin. It also showed large R&D funding outflows tied to new royalty deals.

Nov 2025▲Ligand raised about $445 million of net proceeds from convertible notes and Q3 royalties grew 47% year over year. The added cash supported the royalty acquisition strategy.

Aug 2025▲The Pelthos merger closed and ZELSUVMI launched, leaving Ligand with a 13% royalty and equity upside. Royalty revenue grew 57% year over year in Q2 2025.

May 2025▲Ligand signed a definitive merger agreement for Pelthos and reported 44% royalty growth in Q1 2025. Higher expenses showed the cost of funding new royalty investments and supporting Pelthos before the transaction.

Feb 2025→The 2024 Form 10-K showed 28% royalty growth and several new royalty financing deals. The same filing also flagged higher expenses, an impairment, and generic risk for Evomela.

Nov 2024▲Q3 2024 revenue rose 58% year over year, helped by an Ohtuvayre launch milestone and higher royalties. Filspari also received full FDA approval for IgAN.

Aug 2024→The initial thesis framed Ligand as a royalty and technology licensing company with a low-cost structure. The main tradeoff was clear from the start: diversification helps, but partner control and revenue timing remain key risks.

02 Business model

Paid when partners win

Ligand makes money in three main ways: royalties on partnered drugs, sales of Captisol material, and contract revenue from fees or milestones. Royalties are the core. In Q1 2026, they were $43.0 million out of the company's reported revenue and income categories.

This model can be very attractive. Ligand can collect from many drug programs while keeping its own cost base smaller than a normal biotech company. It also spreads risk across many partners instead of betting the whole company on one lab program.

The catch is control. Ligand usually does not run the drug trials, sales launches, or pricing decisions. If a partner stumbles, a drug disappoints, or a generic arrives, Ligand's cash stream can fall even if Ligand itself executed well.

Capital allocation is the other main lever. Ligand must keep buying or funding the right royalty rights at the right price. The XOMA deal makes that question much bigger.

03 Product portfolio

The royalty basket

Growth engine

XOMA royalty portfolio

The pending acquisition would add over 120 assets. The most important named asset is Roche's Vabysmo, with other rights tied to Ojemda and Miplyffa.

Growth engine

Filspari

Travere's Filspari is now approved for IgAN and FSGS. The FSGS approval on April 13, 2026 made it the first and only FDA approved medicine for that FSGS patient group.

Cash cow

Kyprolis and Evomela

These are meaningful older royalty streams, but they come with patent and generic timelines. A generic Evomela is permitted in the U.S. on June 1, 2026, or earlier under certain terms, and Kyprolis could face generic competition as early as 2027.

Steady

Captisol

Captisol is Ligand's drug solubility technology used in approved partner products. Q1 2026 Captisol revenue fell 36% year over year to $8.7 million because customer orders can shift between periods.

Growth engine

Ohtuvayre and Capvaxive

These newer partnered assets helped drive Q1 2026 royalty growth. Ligand receives a 3% royalty on Ohtuvayre sales.

Option

ZELSUVMI and Xepi

After the Pelthos transaction, Ligand kept upside through a 13% royalty on ZELSUVMI sales outside Japan, an equity stake, and a low single-digit royalty on Xepi. The key test is whether the launch can turn into real royalty cash.

Option

Qtorin rapamycin

Palvella reported positive Phase 3 data for Qtorin rapamycin in microcystic lymphatic malformations. An NDA submission is planned for the second half of 2026.

04 Business segments

Q1 mix was royalty heavy

Royalties83%growing fast

Captisol17%declining

Contract revenue and income0%declining

The mix uses Q1 2026 revenue categories from Ligand's Form 10-Q: royalties, Captisol, and contract revenue and income. The tiny contract line rounds near zero, while royalties dominate the period.

05 Risk factors

What could break the story

XOMA integration and deal math

High impact · Medium odds

The XOMA deal would add over 120 assets, which makes Ligand more diversified. It also makes the company harder to judge. If the acquired assets, especially Vabysmo-linked economics, produce less than expected, the deal could weaken returns even if the headline portfolio looks larger.

We watchClosing in Q3 2026, management's first asset-level contribution comments, and any updated revenue guidance after close.

Viking TR-Beta dispute

Medium impact · Medium odds

Ligand says it terminated the TR-Beta program license, including VK2809 and VK0214. Viking disputes Ligand's right to do that. A bad outcome could mean legal costs, lost economics, or less clarity around a high-interest metabolic disease asset.

We watchAny settlement, lawsuit filing, arbitration update, or SEC filing that changes Ligand's rights to VK2809 or VK0214.

Generic cliffs in older royalties

High impact · High odds

Royalty assets do not last forever. Ligand's filings point to a generic Evomela being permitted in the U.S. on June 1, 2026, or earlier under certain terms. Kyprolis could also see generic competition as early as 2027.

We watchEvomela and Kyprolis sales trends, generic launch dates, and the pace of replacement royalties from newer assets.

Partner execution risk

High impact · Medium odds

Ligand depends on partners to develop, win approval for, manufacture, and sell the drugs. Strong names help, but Ligand does not fully control the launch curve. Weak sales for Filspari in FSGS, Ohtuvayre, ZELSUVMI, or other newer assets would slow the royalty growth story.

We watchQuarterly partner sales for Filspari, Ohtuvayre, ZELSUVMI, Capvaxive, and other named growth assets.

Captisol order swings

Medium impact · High odds

Captisol is useful, but its revenue can be uneven because customers place orders at different times. In Q1 2026, Captisol revenue fell 36% year over year to $8.7 million. That does not kill the thesis, but it can make reported results noisy.

We watchCaptisol quarterly revenue and company comments on whether changes come from timing or lower demand.

Capital deployment discipline

High impact · Medium odds

Ligand's model works only if it buys or funds royalties at prices that leave room for good returns. The company raised about $445 million in net proceeds from convertible notes in 2025, then announced a major cash deal for XOMA in 2026. More money can help, but it can also tempt a buyer to overpay.

We watchNew royalty purchases, upfront payments, funding commitments, and the return assumptions management gives for each deal.

06 Quick answers

In one breath

What does Ligand Pharmaceuticals actually do?

Ligand owns rights to payments from drugs that other companies develop and sell. It also licenses technologies like Captisol, which can help make certain drugs easier to formulate.

Why is the XOMA acquisition important for Ligand?

XOMA would add over 120 assets to Ligand's portfolio. That could reduce dependence on a few older royalties, but it also raises the bar for integration and price discipline.

Why did Filspari matter in 2026?

Filspari was already approved for IgAN. On April 13, 2026, it also won FDA approval for FSGS, opening another rare kidney disease market tied to Ligand's royalty stream.

Is Ligand a normal biotech company?

No. A normal biotech often spends heavily to discover and sell its own drugs. Ligand is more like a royalty owner, so partner success matters more than Ligand running its own sales force.